Duprez Daniel, Ferdinand Keith, Purkayastha Das, Samuel Rita, Wright Richard
Cardiovascular Division, Universityof Minnesota, 420 Delaware St SE, MMC 508, Minneapolis, MN 55455, USA.
Vasc Health Risk Manag. 2011;7:701-8. doi: 10.2147/VHRM.S25743. Epub 2011 Nov 24.
Stage 2 hypertension often requires combination antihypertensive therapy. Ambulatory blood pressure monitoring (ABPM) is a useful tool for assessing antihypertensive drugs and their combinations.
To compare the effect of a moderate dose of angiotensin receptor blocker/calcium channel blocker (ARB/CCB) combined with a diuretic versus a maximal dose of ARB with a diuretic on 24-hour ambulatory blood pressure monitoring (ABPM) and other derived ambulatory blood pressure (ABP) parameters.
The EXforge As compared to Losartan Treatment ABPM substudy was a randomized, double-blind, parallel-group, active-control, forced-titration study of patients with Stage 2 hypertension that compared the efficacy of initial treatment with valsartan/amlodipine 160/5 mg (n = 48) or losartan 100 mg (n = 36). At week 3, hydrochlorothiazide (HCTZ) 25 mg was added in both treatment groups. ABP was measured at baseline and at week 6. Additionaly, 24-hour ABP, nighttime (10 pm to 6 am) and daytime (6 am to 10 pm) ABP, and ABP load (percentage of readings above 140/90 mmHg) were determined.
Eighty-four patients (48 ARB/CCB/HCTZ, 36 ARB/HCTZ) had ABPM at baseline and at week 6. Reductions of systolic/diastolic ABP were greater in the ARB/CCB/ HCTZ group than in the ARB/HCTZ group for 24-hour mean ABP (-22.0/-13.3 versus -17.4/-8.1 mmHg), as well as nighttime ABP (-22.2/-13.3 versus -16.2/-7.4 mmHg), daytime ABP (-21.9/-13.0 versus -18.1/-8.6 mmHg), ABP in the last 4 hours of the dosing period (-21.5/-13.5 versus -17.0/-7.7 mmHg), and ABP load (21.7%/12.8% versus 30.8%/20.0%).
Initiating antihypertensive treatment with moderate doses of ARB/CCB with a diuretic is more effective in lowering nighttime and daytime ABP and reducing ABP load than a maximal dose of an ARB with a diuretic.
2级高血压通常需要联合抗高血压治疗。动态血压监测(ABPM)是评估抗高血压药物及其联合用药的有用工具。
比较中等剂量的血管紧张素受体阻滞剂/钙通道阻滞剂(ARB/CCB)联合利尿剂与最大剂量的ARB联合利尿剂对24小时动态血压监测(ABPM)及其他衍生动态血压(ABP)参数的影响。
与氯沙坦治疗ABPM亚研究相比,EXforge是一项针对2级高血压患者的随机、双盲、平行组、活性对照、强制滴定研究,比较了缬沙坦/氨氯地平160/5mg(n = 48)或氯沙坦100mg(n = 36)初始治疗的疗效。在第3周时,两个治疗组均添加25mg氢氯噻嗪(HCTZ)。在基线和第6周时测量ABP。此外,还测定了24小时ABP、夜间(晚上10点至早上6点)和白天(早上6点至晚上10点)ABP以及ABP负荷(读数高于140/90mmHg的百分比)。
84例患者(48例ARB/CCB/HCTZ,36例ARB/HCTZ)在基线和第6周时进行了ABPM。对于24小时平均ABP(-22.0/-13.3与-17. + 4/-8.1mmHg)、夜间ABP(-22.2/-13.3与-16.2/-7.4mmHg)、白天ABP(-21.9/-13.0与-18.1/- + B.6mmHg)、给药期最后4小时的ABP(-21.5/-13.5与-17.0/-7.7mmHg)以及ABP负荷(21.7%/12.8%与30.8%/20.0%),ARB/CCB/HCTZ组收缩压/舒张压ABP的降低幅度大于ARB/HCTZ组。
与最大剂量的ARB联合利尿剂相比,起始使用中等剂量的ARB/CCB联合利尿剂进行抗高血压治疗在降低夜间和白天ABP以及降低ABP负荷方面更有效。